NCT06505551View on ClinicalTrials.gov

Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

October 31, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2028

Conditions
HPV-Related Squamous Cell CarcinomaHPV-Related Cervical Squamous Cell CarcinomaHPV-Related Vulvar Squamous Cell CarcinomaHPV-Related Penile Squamous Cell CarcinomaHPV-Related Vaginal Squamous Cell CarcinomaHPV-Related Anal Squamous Cell CarcinomaHPV-Related Head and Neck Cancer
Interventions
BIOLOGICAL

SCG142

Autologous SCG142 cells infused on Day 0 after completion of lymphedepletion chemotherapy

DRUG

Cyclophosphamide

for 3 consecutive days

DRUG

Fludarabine

for 3 consecutive days

All Listed Sponsors
lead

SCG Cell Therapy Pte. Ltd.

INDUSTRY

NCT06505551 - Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma | Biotech Hunter | Biotech Hunter